Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
This study has been completed.
Study NCT00307203 Information provided by National Institute on Drug Abuse (NIDA)
First Received: March 23, 2006 Last Updated: September 2, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tobacco-Use Disorder
Schizophrenia
Psychotic Disorders
Additional conditions recognized in this trial
Disease
Tobacco Use Disorder
More general conditions related to this trial
Disorders of Environmental Origin
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Substance-Related Disorders
Interventions listed in this trial
bupropion SR
Cognitive Behavioral Group Therapy
nicotine replacement therapy
Additional drug interventions recognized in this trial
Bupropion
Nicotine
Nicotine polacrilex
More general drug interventions related to this trial
Antidepressive Agents
Antidepressive Agents, Second-Generation
Autonomic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Cholinergic Agents
Cholinergic Agonists
Dopamine Agents
Dopamine Uptake Inhibitors
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Sponsors listed in this trial
National Institute on Drug Abuse (NIDA)
Back to top of Main Content
